Ortho Regenerative Technologies appointed François-Xavier Lacasse to the newly created position of VP of product development.
Dr. Lacasse’s mandate will be development and execution of a comprehensive product development program for Ortho RTi’s novel therapeutic tissue repair devices, including streamlining the company’s preclinical, chemistry, manufacturing, quality control and regulatory affairs activities.
Dr. Lacasse has more than 20 years of drug development experience. Prior to joining Ortho RTi, he held senior consulting and executive leaderships positions with a number of companies, including Anapharm, Xanthus Life Sciences, Supratek Pharma, Merck Frosst and LAB Pharmaceutical Research.
In a statement, Ortho RTi CEO and executive chairman, Dr. Brent Norton, said he is confident that Dr. Lacasse’s expertise will prove to be a tremendous asset as the company continues to advance its proprietary biopolymer platform.
